Mithra Announces 36-month Shelf Life Extension for Tibelia®

  • Extended shelf-life offers competitive advantage over current tibolone-based products, including originator product Livial®
  • Tibelia® is currently marketed in 5 countries through existing supply and license agreements, with further contracts and product launches planned in coming months

Liège, Belgium, 22 novembre 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today confirms the extended shelf-life of 36 months of its complex therapeutic product Tibelia®, as compared to 24 months for other currently available tibolone-based products.